Nevertheless, further therapies targeting α-synuclein aggregation seem a likely development in Lewy body disease in the future, and given the prominent role ascribed to this protein in DLB it seems prudent to evaluate their efficacy in DLB in addition to PD. Here, SNCA is linked to Lewy body dementia.